News

12.10.2021 (Обновлено: 01.04.2022 15:27)

EEC Minister Artak Kamalyan visited Biocad pharmaceutical company

As part of his business trip to St. Petersburg, Artak Kamalyan, Minister in charge of Industry and Agriculture of the Eurasian Economic Commission, visited the research and production center of Biocad pharmaceutical company.

During the visit, Artak Kamalyan inspected production lines, scientific and laboratory facilities as well as discussed prospects for developing pharmaceuticals with the Company's management.

The EEC Minister informed on the measures taken by the Commission in this field as well as elaborating an action plan to increase the supply of vitally important medicines and pharmaceutical substances for human use the manufacture of which should be established in the EAEU by 2024 for the Eurasian Economic Union States.

"Our objective is to create such conditions for the pharmaceutical business in which it will be able to develop in a sustained way, manufacturing modern competitive products and thereby meet the needs of the internal market", Artak Kamalyan said. “We believe that implementing our plan measures and joining the research and production potentials of the EAEU countries will give a tangible synergistic effect. This factor will not only contribute to stabilizing the Union’s pharmaceutical market which is still very unbalanced due to the consequences of the first wave of the COVID-19 coronavirus pandemic, but will also bring innovations to the current market model".

Artak Kamalyan has stressed that the disposition to prepare the plan was adopted at the Supreme Eurasian Economic Council’s meeting held on May 21 this year. The central objective of this work is to increase the supply of vitally important medicines for the EAEU countries and to launch their manufacture in the Union. The EEC Minister noted its strategic importance for each of the Eurasian States.

In turn, representatives of Biocad pharmaceutical company reported on the range of manufactured products, including the vaccine against coronavirus being developed on its own gene therapy platform. The official permit to start clinical trials of the pharmaceutical was issued by the Ministry of Health of the Russian Federation in July of this year.

Aleksey Torgov, Deputy Director General of Biocad, CJSC, noted the importance and timeliness of the work carried out by the Commission on developing the EAEU pharmaceutical industry. 


For reference

Biocad, CJSC is the Russian innovative biotechnological company founded in 2001. It unites research and development centers, pharmaceutical and biotechnological production, a system of preclinical and clinical research and has extensive experience in creating and manufacturing original pharmaceutical substances and medicines to treat cancer, autoimmune and orphan diseases. Sputnik V and Sputnik Lite vaccines are manufactured at the Company's production facilities.